The company manufactures reactive dyes and dye intermediates primarily for the textile industry, serving both domestic and international markets from its facility in Gujarat.
The company operates in a highly fragmented and commoditized specialty chemicals segment where margins are volatile and returns on capital are mediocre (11.3%). While the company claims a brand advantage with 'Shlokka Dyes,' the lack of pricing power and the negative cash conversion cycle suggest no durable competitive advantage exists.
Management has prioritized aggressive capacity expansion and the acquisition of a promoter-owned entity, yet these investments have coincided with a sharp decline in EPS and poor cash flow. The use of IPO proceeds for working capital beyond stated limits suggests a lack of disciplined financial planning.
The collapse was driven by the inevitable collision between aggressive revenue scaling and a complete lack of cash generation. Management’s habit of diverting capital to third parties and promoter-owned entities eventually drained the balance sheet, leaving the company unable to service its debt as the negative cash conversion cycle worsened. The massive divergence between top-line growth and bottom-line losses proved to be a harbinger of structural insolvency rather than temporary scaling pains, resulting in a total loss of investor confidence and a liquidity crisis.
RichFakir rates Shlokka Dyes Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Shlokka Dyes Ltd is trading about 13% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Shlokka Dyes Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Shlokka Dyes Ltd's fair value is about ₹50 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →